Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
The use of adeno-associated virus (AAV) as a gene therapy vector has been approved recently for clinical use and has demonstrated efficacy in a growing number of clinical trials. However, the safety of AAV as a vector has been challenged by a single study that documented hepatocellular carcinoma (HCC) after AAV gene delivery in mice. Most studies have not noted genotoxicity following AAV-mediated gene delivery; therefore, the possibility that there is an association between AAV and HCC is controversial. Here, we performed a comprehensive study of HCC in a large number of mice following therapeutic AAV gene delivery. Using a sensitive high-throughput integration site-capture technique and global expressional analysis, we found that AAV integration into the RNA imprinted and accumulated in nucleus (Rian) locus, and the resulting overexpression of proximal microRNAs and retrotransposon-like 1 (Rtl1) were associated with HCC. In addition, we demonstrated that the AAV vector dose, enhancer/promoter selection, and the timing of gene delivery are all critical factors for determining HCC incidence after AAV gene delivery. Together, our results define aspects of AAV-mediated gene therapy that influence genotoxicity and suggest that these features should be considered for design of both safer AAV vectors and gene therapy studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“preclinical data suggest AAV integration events occur in a dose-dependent manner with a preference for integration at sites of active transcription, tissue-specific promoters are protective against oncogenesis.178, 179, 180”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [179]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cutadapt removes adapter sequences from high-throughput sequencing reads
Martin, M. (2011) · EMBnet.journal · doi:10.14806/ej.17.1.200 · Cited by 33,889 · cited 1×
“GCGCGCTCGCTCG-3′) were trimmed by cutadapt (57).”
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400 · cited 2×
“Mouse BLAT (61, 62) (assembly December 2011 Genome Reference Consortium Mouse Build 38/mm10) was used to align the resultant sequence to the murine genome.”
<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool
Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480 · cited 2×
“Mouse BLAT (61, 62) (assembly December 2011 Genome Reference Consortium Mouse Build 38/mm10) was used to align the resultant sequence to the murine genome.”
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 1×
“To investigate this possibility, we developed a vector, AAV8-hAAT-synMUT, modeled on a AAV vector that had been administered to human subjects with hemophilia and did not cause genotoxicity in mice (13, 33).”
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“In fact, there are multiple human AAV gene therapy trials around the world that have been completed, are accruing participants, or are in preparation (4), and recent studies using AAV to treat 3 genetic disorders have been regarded as successful (5–8).”
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“The most relevant example is the failure of animal studies to predict the increased risk for the development of leukemia after retroviral gene therapy for X-linked severe combined immunity deficiency (45).”
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 2×
“…the use of a more hepatotrophic serotype, such as AAV8 compared with AAV2, led to an increase in the rate of HCC. Additionally, the use of distinct capsids to pseudotype AAV vectors (48), such as serotypes 8 and 9, confers distinct patterns of tissue troph-ism in wild-type and disease states (49).”
Research works printed but not linked: 1
- Martin, 2011, EMBnetJ., 17
Cited by
Items 301–400 of 422
Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1
Ates, I., Stuart, C., Rathbone, T., Barzi, M., He, G., Major, A. M., Shankar, V., Lyman, R. A., Angner, S. S., Mackay, T. F. C., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000424 · Cited by 6
“[25,26] Since AAVs exist as stable episomes, there are concerns that persistent Cas9 expression increases off-target activity and genotoxicity.”
AAV Vector-Based Gene Therapy, Progress and Current Challenges
Kuranda, K., & Mingozzi, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_5 · Cited by 5
Manson, M. A., Zhang, F., Novokhodko, A., Chen, C., Parker, M. H., Loeb, K. R., Kajimoto, M., Campbell, C., Storb, R. F., & Miao, C. H. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006016 · Cited by 5
Long-Term Liver-Targeted AAV8 Gene Therapy for Mucopolysaccharidosis IVA
Khan, S. A., Benincore-Flórez, E., Nidhi, F., Álvarez, J. V., Holder, D. A., & Tomatsu, S. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47110900 · Cited by 5
The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art
Minno, G. D., Spadarella, G., Calcaterra, I. L., Castaman, G., Simioni, P., CRISTOFARO, R. D., Santoro, C., Peyvandi, F., & Minno, M. N. D. D. (2024) · Bleeding Thrombosis and Vascular Biology · doi:10.4081/btvb.2024.144 · Cited by 4
AAV-mediated genome editing is influenced by the formation of R-loops
Puzzo, F., Crossley, M. P., Goswami, A., Zhang, F., Pekrun, K., Garzon, J. L., Cimprich, K. A., & Kay, M. A. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.09.035 · Cited by 4
mRNA and gene therapy for diabetes: The next-generation treatment frontiers
Mourya, A. K., Jindal, N., & Kumar, A. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103706 · Cited by 4
Expanding the Potential of Gene Therapy for Duchenne Muscular Dystrophy
Khan, G., & Hussain, M. S. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128386290250507101412 · Cited by 4
Molybdenum Cofactor and Sulfite Oxidase Deficiency
Reiss, J. (2016) · Journal of Postgenomics Drug & Biomarker Development · doi:10.4172/2153-0769.1000184 · Cited by 5
“By now, a large body of evidence has accumulated that AAV applications can increase the risk for hepatocellular carcinoma (HCC), but also that this risk can be minimized by modulating several parameters such as vector dose or enhancer/promoter selection [43].”
BackgroundBrunetti‐Pierri, N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817344-2.00030-7 · Cited by 5
Closing In on Treatment for Hemophilia B
Porteus, M. H. (2017) · New England Journal of Medicine · doi:10.1056/nejme1713735 · Cited by 4
SACF and GILA assays on AML12 cells show limited predictive value for mouse liver genotoxicity
Coratella, E., Bohnert, R., Fischer, B., Lemmens, M., Alpert, T., Beibel, M., Oertli, M., Naumann, U., Elhajouji, A., Odermatt, A., et al. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117529 · Cited by 3
RAAVioli: A comprehensive approach to characterizing AAV vector integrations and rearrangements
Cipriani, C., Rudilosso, L., Dalwadi, D. A., Masseroli, M., Grompe, M., Montini, E., Calabria, A., & Cesana, D. (2025) · Molecular Therapy Advances · doi:10.1016/j.omta.2025.201659 · Cited by 5
“12,15,19,20 A single case of HCC was also reported in a patient receiving liver-directed AAV5 therapy for hemophilia B, 21 and other reports have highlighted connections between human HCCs and natural AAV infections.”
Ismail, A. M., Witt, E., Bouwman, T., Clark, W. T., Yates, B., Franco, M., & Fong, S. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101294 · Cited by 4
“…vector is administered during the neonatal period or in some adult mouse models of disease, such as chronic in fl ammation, obesity, and diabetes, 18,30 – 34 if the 3 0 untranslated region of the wild-type AAV2 genome with liver-speci fi c promoter activity is left intact, 35,36 or if high doses…”
InfluentialProspects of gene and cell therapy for managing cardiac complications in Friedreich ataxia
Isaacs, C. J., Shinnick, J. E., Schadt, K. A., Lynch, D. R., & Lin, K. Y. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1083854 · Cited by 3
“However, a large study of mice treated with AAV 2, 8 and 9 vectors in a variety of trials concluded that mice treated with AAV vectors were more likely to develop hepatocellular carcinoma (HCC) regardless of mouse genotype or type of viral transgene [104].”
BackgroundStudies on glycogen storage disease type 1a animal models: a brief perspective
Petrova, I. O., & Smirnikhina, S. (2022) · Transgenic Research · doi:10.1007/s11248-022-00325-7 · Cited by 3
Monitoring for liver cancer post‐gene therapy—How much and how often?
de Jong, Y. P., & Jacobson, I. M. (2024) · Journal of Viral Hepatitis · doi:10.1111/jvh.13898 · Cited by 4
Qiu, L., Kumpf, S. W., Oziolor, E. M., Sheehan, M. J., Finley, J. E., Rubitski, D. M., Qian, J., Gosink, M. M., Kopec, A. K., Lanz, T. A., et al. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117229 · Cited by 3
Riordan, J. D. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.045 · Cited by 3
“Of 37 HCC-associated rAAV integration sites in Rian from three independent mouse studies, 3–5 21 (57”
Malignancy and gene therapy in hemophilia
Kaczmarek, R. (2025) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2025.103283 · Cited by 2
“Multiple studies have seen hepatocellular carcinoma (HCC) in mice that received recombinant AAV, with an incidence as high as 50% to 70% compared with a background incidence below 10% [8].”
Gasperetti, A., Calkins, H. G., & Barth, A. S. (2026) · Heart Rhythm · doi:10.1016/j.hrthm.2026.03.1942 · Cited by 2
Halagali, P., Seenivasan, R., Sreedevi, A., Ligade, V. S., Bugadannavar, P., Sharma, H., Nand, S., & Tippavajhala, V. K. (2026) · 3 Biotech · doi:10.1007/s13205-026-05016-2 · Cited by 5
“Factors such as vector dose, choice of enhancer/promoter elements, and timing of administration greatly influence genotoxicity (Chandler et al. 2015).”
Impoverished Conceptions of Gene Causation and Therapy in Developmental Neurology
Pascual, J. M., Jakkamsetti, V., Málaga, I., & Noble, D. (2023) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2023.07.017 · Cited by 2
Sakurai, F., Iizuka, S., Tsukamoto, T., Shiota, A., Shimizu, K., Ohashi, K., & Mizuguchi, H. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.022 · Cited by 3
Libertini, S., Jadlowsky, J. K., Lanz, T. A., Mihalcik, L., & Pizzurro, D. M. (2024) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22633 · Cited by 2
“…associated with development of hepatocellular carcinoma (HCC) following injection of recombinant AAV (rAAV) in neonatal mice (Chen et al., 2024; Chandler et al., 2015; Donsante et al., 2007) or adult mice with damaged liver (Dalwadi et al., 2021), though no evidence of HCC has been shown in…”
Pascual, J. M., & Noble, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00028-5 · Cited by 3
Modulation of AAV transduction and integration targeting by topoisomerase poisons
Kasimsetty, A., Hwang, Y., Everett, J. K., McFarland, A. G., Zolnoski, S. A., Lu, T., Roche, A. M., Martínez‐García, P. M., Sabatino, D. E., & Bushman, F. D. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101364 · Cited by 2
“Because integration of AAV can promote vector persistence in dividing cells, 6 but may also increase risk of genotoxicity, 7,8 it is important to understand the mechanisms and consequences in detail.”
Jin, X., Ye, Q., Wu, X., Su, J., Song, L., Fu, J., Qiuxia, X., Luo, M., Liu, F., Ren, C., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00741 · Cited by 2
“Studies have shown that the enhancer and promoter design used in recombinant AAV vectors is correlated with HCC risk [46].”
Prospect and progress of gene therapy in acute intermittent porphyria
D’Avola, D., & González‐Aseguinolaza, G. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1191346 · Cited by 2
“An additional important finding of this study regarding the vector safety is related to one of the major concerns recently raised in the field of clinical application of recombinant AAV vectors: the association of wt AAV and recombinant AAV with the development of hepatocellular carcinoma [42,43].”
BackgroundGene Therapy for X-Linked Myotubular Myopathy
Dupont, J.-B., Lawlor, M. W., & Childers, M. K. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_32 · Cited by 2
Recent advances towards gene therapy for propionic acidemia: translation to the clinic
Barry, M. A. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1635883 · Cited by 2
Immunotherapy in Alzheimer’s Disease
Gupta, J., & Hoque, M. (2019) · Springer eBooks · doi:10.1007/978-981-13-9636-6_14 · Cited by 2
Plasmids – vectors for gene therapy
Zaleski, P., Wawrzyniak, P., Sobolewska, A., & Płucienniczak, G. (2017) · Postępy Mikrobiologii - Advancements of Microbiology · doi:10.21307/pm-2017.56.2.214 · Cited by 2
Priya, N. M., Kumar, S. U., Kumar, D. T., Magesh, R., Siva, R., Ramanathan, G., & Doss, C. G. P. (2022) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.07.003 · Cited by 2
Suleman, S., Khalifa, M. S., Fawaz, S., Alhaque, S., Chinea, Y., & Themis, M. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.121 · Cited by 2
Gene therapy for hemophilia: Recent developments and challenges (Review)
Abdulnabi, M. A., Al‐Saadi, E. A. K. D., & Al‐Bayaa, I. M. (2025) · World Academy of Sciences Journal · doi:10.3892/wasj.2025.329 · Cited by 1
“Previous studies, however, have demonstrated that hepatocellular carcinoma can develop in neonatal mouse models following recombinant AAV gene transfer (72).”
Recombinant AAV gene transfer: Emerging applications in immune modulation and cancer therapy
Yang, Y., Chen, R., Bao, Y., Han, H., Ma, K., Pei, X., Zhang, L., & Shao, W. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117332 · Cited by 2
Nucleic acid-encoded antibody gene transfer-next generation of antibody therapies
Yu, K., Xiao, G., Chen, B., Xu, N., & Liu, W. (2025) · Drug Delivery · doi:10.1080/10717544.2025.2566782 · Cited by 1
“However, most clinical studies focusing on moderate-dose support that AAv delivery is well tolerated in clinical practice and has achieved clinical effects in specific applications (chandler et al. 2015).”
The future of clinical studies of in-utero therapy for genetic diseases
Gough, G., Schaefer, G. O., Lim, K. M. X., Choolani, M. A., & Mattar, C. N. Z. (2025) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2025.102678 · Cited by 1
Mohanta, Z., Singh, A., López-Bertoni, H., Sall, S., Stabinska, J., Manoli, I., Vernon, H. J., Venditti, C. P., Gilad, A. A., & McMahon, M. T. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.11.014 · Cited by 2
Self-citationLiver dysfunction in AAV-mediated Hemophilia B gene therapy: Mechanisms and management strategies
Song, X., Ding, B., Jia, H., & Zhou, H. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101356 · Cited by 2
Wu, Z., Liu, H., & Wu, D. (2025) · Medical Oncology · doi:10.1007/s12032-025-03158-6 · Cited by 1
“Long-term monitoring (>6 months) of AAV-Cas13d-PGGC in pancreatic cancer mod - els revealed no significant genomic abnormalities, though high-dose administration (≥ 1 × 10¹⁴ vg/kg) induced low-frequency integration events in liver tissues, highlighting dose-dependent genotoxicity [ 123, 124 ].”
Mole, A. J., Sander, C., Parmar, A., Williams, A. J., Azzouz, M., Hautbergue, G. M., Shaw, P. J., Ferraiuolo, L., & Mead, R. J. (2026) · Scientific Reports · doi:10.1038/s41598-026-38039-z · Cited by 2
“In contrast, direct injection into cerebrospinal fluid (CSF) allows for precise targeting of specific CNS regions or cell populations but may require more invasive procedures that pose risk of tissue damage or immune responses.”
Анатольевна, Р. О., Melnikova, E. V., & Merkulov, V. A. (2026) · Innovative medicine of Kuban · doi:10.35401/2541-9897-2026-11-1-148-156 · Cited by 1
Becker, R., Choudhury, P., Oti, M., Fouani, Y., Strobel, B., Ketterer, S., Rumpel, S., Park, J., Kreuz, S., Maier, U., et al. (2026) · iScience · doi:10.1016/j.isci.2026.115469 · Cited by 1
“…designs have marked significant steps forward for gene therapy, beyond the use of strong ubiquitous promoters such as CMV, which can pose the risk for unregulated transgene expression leading to toxicity 17,18 or can be prone to silencing, resulting in a loss of therapeutic transgene expression.”
The Evolving Landscape of Fetal Therapy: Surgical Interventions and Emerging Biologics
Yılmaz, B. Ş., Hill, M. K., Baranello, G., Loukogeorgakis, S., Coppi, P. D., Gissen, P., & Chitty, L. S. (2026) · Biologics · doi:10.3390/biologics6020011 · Cited by 1
“Although adenoviruses and AAVs are generally considered to pose a lower risk of insertional mutagenesis, preclinical studies have reported the development of carcinoma in fetal mice following injection not only with lentiviral vectors but also with non-integrating vectors like AAV [144,145].”
Gene therapy for aging: Current evidence and future directions
Zhang, Y. C., Gan, L., Wang, S., & Zhang, J. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103144 · Cited by 1
Yang, W., Li, A., Dong, B., Feng, X., & Jiang, F. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108902 · Cited by 1
Scott, S., Hallwirth, C. V., Sasaki, N., Cunningham, S. C., Zhu, E., Khandekar, N., Kizana, E., Baruteau, J., Gissen, P., Perocheau, D. P. B., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.07.039 · Cited by 1
Evaluating cases of possible insertional mutagenesis after AAV gene therapy
George, L. A., Ahrens‐Nicklas, R. C., & Bushman, F. D. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.07.026 · Cited by 1
Recent progress in gene therapies for mucopolysaccharidoses
Ginocchio, V. M., & Brunetti‐Pierri, N. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1529564 · Cited by 1
“The same integration site was observed in more recent studies in methylmalonic acidemia mice which also developed HCC several months after neonatal AAV injection [90].”
BackgroundResultAsp, P., Guha, C., Chowdhury, N. R., & Chowdhury, J. R. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch73 · Cited by 1
State of the art on clinical trials of gene therapy in haemophilia
Garagiola, I., & Peyvandi, F. (2020) · doi:10.36118/pharmadvances.03.2020.05 · Cited by 1
“model and others suggest a tumour suppressive role (21-25).”
BackgroundShi, K., Liang, C., Huang, X., Wang, S., Chen, J., Cheng, F., Wang, C., Ying, L., Pan, Z., Zhang, Y., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202201824 · Cited by 1
Meeting Summary: ESGCT 2022 AAV Safety Plenary Session
Gallagher, T. F. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.29230.tga · Cited by 1
“14 In humans, chronic diseases such as infection with Hepatitis A or B, diabetes, nonalcoholic fatty liver disease, and chronic alcohol consumption are major risk factors for HCC.”
Random Integration Analysis of Recombinant Adeno-Associated Virus 6 Packaged in Sf9 Insect Cells
Zhang, M., Liu, X., & Zhang, C. (2023) · Molecular Biology · doi:10.1134/s0026893323040209 · Cited by 1
Random Integration Analysis of Recombinant Adeno-Associated Virus 6 Packaged in Sf9 Insect Cells
Zhang, M., Liu, X., & Zhang, C. (2023) · Molecular Biology · doi:10.31857/s0026898423040262 · Cited by 1
A dual role for adeno-associated virus in human health
Araujo, N. M. (2023) · Virology Journal · doi:10.1186/s12985-023-02196-8 · Cited by 2
“Despite the two independent mouse models of AAV vectorization that developed HCC by insertional mutagenesis [22, 23], the risk of rAAV-mediated oncogenesis in humans is theoretical since no confirmed genotoxic events have been documented to date [24].”
BackgroundBiomarker and Bioanalytical Readouts for the Development of AAV Gene Therapy
Lu, Y., & Lembke, W. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch3 · Cited by 1
Intrauterine Fetal Therapy: Past, Current, and Future
Kamel, R. M. A., Soliman, M. M. H., Bagunaid, M. A., Radwan, M. A., Moallem, A. A., Borah, M., & Al-Murad, B. M. (2025) · Open Journal of Obstetrics and Gynecology · doi:10.4236/ojog.2025.153030 · Cited by 1
Progress and challenges in gene therapy for Crigler–Najjar syndrome
Aronson, S. J., Beuers, U. H., & Bosma, P. J. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1100991 · Cited by 1
rAAV-based gene therapy for molybdenum cofactor deficiency type B
Jakubiczka-Smorag, J. (2015) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5161
Virus-mediated Delivery of the Fmr1 Gene as a Tool for the Treatment of Fragile X Syndrome
Moghaddam, S. G. (2016) · TSpace (University of Toronto)
Intracellular fate of AAV particles in human Dendritic Cell and impact on Gene Transfer
Rossi, A. (2016) · theses.fr (ABES) · doi:10.70675/4518d4eazdbd8z4f46z96e2zf87942913c70
“Exempli gratia (“for example”) EC: Endothelial cell EE: Early endosome EGFR: Epidermal growth factor receptor ELISA: Enzyme-linked immunosorbent assay ELIspot: Enzyme-linked immunospot EMA: European medical agency epDNA: Episomal DNA ER: Endoplasmic reticulum etc. Lat. et cetera (“and the rest”) F. FACS: Fluorescence-…”
BackgroundHelper-Dependent Adenoviral Vectors for Gene Therapy of Inherited Diseases
Piccolo, P., & Brunetti‐Pierri, N. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_4
Nault, J. (2015) · theses.fr (ABES) · doi:10.70675/1be42c8azb025z49fczabeczf2d92c0f0126 · Cited by 2
Warischalk, J. K. (2015) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/dqdt-1s58 · Cited by 1
Intravenously administered gene therapy for neuronopathic Gaucher disease
Massaro, G. (2018) · UCL Discovery (University College London) · Cited by 1
Gene Therapy: Principles and Clinical Potential
Buckley, S. M. K., & David, A. L. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108564434.053
Martin, M. J. (2020) · Mspace (University of Manitoba)
Novel approaches in long term mechanical circulatory support
Morley-Smith, A. C. (2017) · doi:10.25560/80372
Mingozzi, F., & Junge, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-63671-1.00033-1
Assaf, B. T., Harper, C. G., & Phillips, J. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00034-8 · Cited by 2
Chandler, R. J. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.04.006
“Since this approach utilizes the endogenous G6PC promoter, the risk of toxicity from transgene overexpression and genotoxicity from the use of strong exogenous enhancer and promoter are reduced.(9)”
BackgroundSelf-citationBlood-brain barrier-directed gene therapy as a strategy to treat Niemann-Pick type C2 disease
Rasmussen, C. L. M. (2022) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau528833295
Genome Integration of Adeno-associated Virus (AAV) Vectors into Infected Cells
Hirai, Y. (2023) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.19.211
Intrathecal Delivery of Viral Vector-Mediated Gene Therapy
Keifer, O. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-39558-1_16
Recent Development in in vivo Clinical Gene Therapy Platforms
Murphy, J. E., & Owens, J. M. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch2
rAAV Integration: Detection and Risk Assessment
Yuan, J., Gil-Fariña, I., Fronza, R., & Whiteley, L. O. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch13
Vector-Mediated Genotoxicity and Mutagenicity in Hematopoietic Stem Cell Gene Therapy
YILMAZ, S., & Kartal, Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00100-1
Preclinical development of viral vector gene therapies
Newman, M. S., Hudry, E., Brassard, J. A., & Cunningham, J. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13344-2.00003-1
Kropp, M. (2025) · Archive ouverte UNIGE (University of Geneva) · doi:10.13097/archive-ouverte/unige:185728
Breton, C. A., Clark, P., Wang, L., Greig, J. A., & Wilson, J. M. (2020) · Figshare · doi:10.6084/m9.figshare.11999370
Breton, C. A., Clark, P. M., Wang, L., Greig, J. A., & Wilson, J. M. (2020) · Figshare · doi:10.6084/m9.figshare.11999367
Breton, C. A., Clark, P., Wang, L., Greig, J. A., & Wilson, J. M. (2020) · Figshare · doi:10.6084/m9.figshare.11999373
Liver-directed gene editing with crispr-cas9
Singh, K. (2023) · VUBIR (Vrije Universiteit Brussel)
Gene, genetics and genetic medicines in gastroenterology: Current status and its future
Kumar, A., Sarangi, Y., & Kaw, P. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i1.112496
“Refinement of the vector systems may reduce this error[216,217].”
Balancing Promise and Peril: Hemophilia Gene Therapy Insights
Akula, S., Borroni, E., Cottonaro, A., Follenzi, A., & Merlin, S. (2026) · IUBMB Life · doi:10.1002/iub.70087
“…of AAV-mediated insertional mutagenesis observed in neonatal mice, while studies with older (juvenile/ adult) mice were not able to demonstrate AAV-induced tumorigenesis or to correlate the increased incidence of tumor formation in treated mice to AAV-mediated insertional mutagenesis [99, 100].”
Asgarian, Z. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.047
Dirvelytė-Valauskė, E., Mazerimas, M., Pavliukevičienė, B., Daugelaviciene, N., Kutanovas, S., Kao, C.-Y., Chen, Y., Neniškytė, U., & Budvytytė, R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.10.710763
“Yet, despite their eYicacy, viral vectors pose risks, including immunogenicity (5) and genotoxicity (6).”
Umeshita, S., Imanishi, K., Likhite, S. B., Ito, M., Takino, N., Meyer, K., Kinoshita, T., Muramatsu, S., & Murakami, Y. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201724
“15 Although no human cases treated with an AAV vectors driven by CBA have developed liver cancer to date, a promoter that provides the minimum required expression of PIGO is considered safer.”
Régénération hépatique : stimulus pour la transplantation d'hépatocytes
Tranchart, H. (2017) · theses.fr (ABES) · doi:10.70675/8bab0deez1ae3z4505z8202ze50c47df4b99
Chansel‐Debordeaux, L. (2017) · theses.fr (ABES) · doi:10.70675/6b80556ez59a7z4009za535zb2fd974484d2
Découverte et validation de nouveaux biomarqueurs de l'insuffisance cardiaque
Barutaut, M. (2016) · theses.fr (ABES) · doi:10.70675/b354b3dbzae60z44d4za8d2zb6135342310e
Boukhalfa, I. (2017) · theses.fr (ABES) · doi:10.70675/f17724cbz825ez4a0az9c31z0b10d6d5f706 · Cited by 1
Sargent, D. (2018) · theses.fr (ABES) · doi:10.70675/2cd4ead6z0cd7z476dz8376z54bb3bd9a0ea
Metadata
- Authors
- Chandler, R. J., LaFave, M. C., Varshney, G. K., Trivedi, N. S., Carrillo-Carrasco, N., Senac, J. S., Wu, W., Hoffmann, V., Elkahloun, A. G., Burgess, S. M., & Venditti, C. P.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2015-01-20
- Volume
- 125
- Issue
- 2
- Pages
- 870-880
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4319425
- OpenAlex
- W2133112334
- Cited by
- 403
- References
- 63
- Citations by year
- 2026: 28 · 2025: 42 · 2024: 40 · 2023: 38 · 2022: 36 · 2021: 32 · 2020: 45 · 2019: 30 · 2018: 26 · 2017: 32 · 2016: 31 · 2015: 22
- FWCI
- 25.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- adeno-associated virus, gene therapy vectors, hepatocellular carcinoma, genotoxicity, AAV integration, microRNA overexpression, RTL1, vector dose
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Carcinoma, Hepatocellular, Liver Neoplasms, Mice, Mutant Strains, Pregnancy Proteins, Transduction, Genetic, Genetic Therapy, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.